Friday, 23 December 2022
Researchers have today released findings from a clinical trial investigating the effectiveness of the antiviral treatment molnupiravir against COVID-19 – the first treatment tested in the ongoing PANORAMIC trial.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of COVID-19 In the Community () was developed by Professor Sir Jonathan Van-Tam, Pro-Vice-Chancellor for the Faculty of Medicine & Health Sciences at the ÌÇÐÄÔ´´, and Chris Butler, Professor of Primary Care in the Nuffield Department of Primary Care Health Sciences and co-Chief Investigator of PANORAMIC.
PANORAMIC is led by a team of researchers at the University of Oxford and funded by UK Research and Innovation (UKRI) and National Institute for Health and Care Research (NIHR). (NIHR135366). The trial is being used to identify which groups of higher risk people were most likely to benefit from new antiviral treatments for COVID-19. The study allows multiple antiviral drugs to be tested in parallel.
In the paper published in The Lancet, they reported that molnupiravir did not reduce hospitalisations or deaths among higher risk, vaccinated adults with COVID-19 in the community. The treatment was, however, associated with a faster recovery time and reduced viral detection and load – participants who received molnupiravir reported feeling better compared to those who received usual care.
Professor Sir Jonathan Van-Tam
Commenting on the findings, Professor Sir Jonathan Van-Tam said: "While molnupiravir was originally found to work well to reduce hospitalisation in patients with Covid, these were unvaccinated patients.
“This latest research has repeated the exercise in the highly vaccinated population, demonstrating that the vaccine protection is so strong that there is no obvious benefit from the drug in terms of further reducing hospitalisation and deaths.
“However, symptom duration and virus shedding are both markedly reduced, and we must wait much longer to know if there will be any discernible effects on Long Covid.
“This study is an excellent example of why large-scale, rigorous, prospective trials like this are so essential in assessing the effectiveness of drugs to ensure that they are only used in patients where there will be a tangible benefit to their care."
Chris Butler, Professor of Primary Care in the Nuffield Department of Primary Care Health Sciences and co-Chief Investigator of PANORAMIC, said: “Finding effective, safe and scalable early treatments for COVID-19 in the community is the next major frontier in our research response to the ongoing worldwide pandemic. It is in the community where treatments could have a massive reach and impact. But decisions about who to treat should always be based on evidence from rigorous clinical trials that involve people who would most likely be prescribed the drugs.
“The evidence PANORAMIC has produced about molnupiravir will guide treatment decisions for COVID-19 world-wide. It is rapidly generating critically important clinical evidence from within the pandemic to guide care during the pandemic itself, in this case determining effects of molnupiravir among people who are almost all vaccinated.
“We must not forget the other ongoing pandemic of antibiotic resistance, which in part stems from using antimicrobial drugs at scale before we did rigorous clinical trials to find out who really benefits form treatment, and who does not. The PANORAMIC team is also doing the necessary trials and gathering evidence about these treatments before we go straight to widespread use.”
The study will now continue to investigate new antiviral medications such as Paxlovid. For more information or to enrol, please visit .
Story credits
For further information, please email news.office@admin.ox.ac.uk or call 01865 280528, or contact Adam Mallaby,Media Relations Manager at the ÌÇÐÄÔ´´, on +44 (0)115 748 5719 oradam.mallaby@nottingham.ac.uk
Notes to editors:
About the ÌÇÐÄÔ´´
Ranked among the world's top 100 universities , the ÌÇÐÄÔ´´ delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what’s next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the ÌÇÐÄÔ´´ invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we’re creating knowledge, opportunity and solutions that help change what's next.